Tiziana Life Sciences PLC (LSE:TILS, NASDAQ:TLSA, FRA:RTRA, OTC:TIZAF)'s Dr Kunwar Shailubhai speaks to Proactive following the news of a License Agreement with Precision BioSciences Inc to explore Tiziana's foralumab, a fully human anti-CD3 monoclonal antibody, as an agent to induce tolerance of allogeneic CAR T cells to potentially improve the clinical outcome of CAR T cell therapy. Precision will be responsible for the development, commercialization, and costs for use of foralumab, and Tiziana will receive upfront payment, certain milestone payments, and royalties for foralumab.
Tiziana Life Sciences welcomes license deal for foralumab in CAR T cell therapy
